What is a stock summary page? Click here for an overview.
Business Description
Aerovate Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US0080641071
Description
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 188.54 | |||||
| Equity-to-Asset | 0.95 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -11.6 | |||||
| 3-Year EPS without NRI Growth Rate | -9.3 | |||||
| 3-Year FCF Growth Rate | -3.6 | |||||
| 3-Year Book Growth Rate | -28 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.17 | |||||
| 9-Day RSI | 53.07 | |||||
| 14-Day RSI | 52.65 | |||||
| 3-1 Month Momentum % | -10.45 | |||||
| 6-1 Month Momentum % | 20.6 | |||||
| 12-1 Month Momentum % | -91.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 20.93 | |||||
| Quick Ratio | 20.93 | |||||
| Cash Ratio | 20.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.9 | |||||
| Shareholder Yield % | -33 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -77.08 | |||||
| ROA % | -67.31 | |||||
| ROIC % | -2756.49 | |||||
| 3-Year ROIIC % | 1070.75 | |||||
| ROC (Joel Greenblatt) % | -11554.52 | |||||
| ROCE % | -82.35 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.94 | |||||
| Price-to-Tangible-Book | 0.94 | |||||
| EV-to-EBIT | 0.07 | |||||
| EV-to-EBITDA | 0.07 | |||||
| EV-to-FCF | 0.07 | |||||
| Price-to-Net-Current-Asset-Value | 0.95 | |||||
| Price-to-Net-Cash | 0.97 | |||||
| Earnings Yield (Greenblatt) % | 1428.57 | |||||
| FCF Yield % | -98.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AVTE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aerovate Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.44 | ||
| Beta | 1.08 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 0.48 | ||
| Volatility % | 100.8 | ||
| 14-Day RSI | 52.65 | ||
| 14-Day ATR ($) | 0.080493 | ||
| 20-Day SMA ($) | 2.50725 | ||
| 12-1 Month Momentum % | -91.76 | ||
| 52-Week Range ($) | 1.25 - 30.29 | ||
| Shares Outstanding (Mil) | 28.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aerovate Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aerovate Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aerovate Therapeutics Inc Frequently Asked Questions
What is Aerovate Therapeutics Inc(AVTE)'s stock price today?
The current price of AVTE is $2.49. The 52 week high of AVTE is $30.29 and 52 week low is $1.25.
When is next earnings date of Aerovate Therapeutics Inc(AVTE)?
The next earnings date of Aerovate Therapeutics Inc(AVTE) is 2025-05-13 Est..
Does Aerovate Therapeutics Inc(AVTE) pay dividends? If so, how much?
Aerovate Therapeutics Inc(AVTE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers